CA1095930A - Process for the preparation of new derivatives of taurine having a reinforced neuro-muscular activity - Google Patents

Process for the preparation of new derivatives of taurine having a reinforced neuro-muscular activity

Info

Publication number
CA1095930A
CA1095930A CA299,464A CA299464A CA1095930A CA 1095930 A CA1095930 A CA 1095930A CA 299464 A CA299464 A CA 299464A CA 1095930 A CA1095930 A CA 1095930A
Authority
CA
Canada
Prior art keywords
taurine
neuro
preparation
taurinate
reinforced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA299,464A
Other languages
English (en)
French (fr)
Inventor
Jean P. Durlach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cooperation Pharmaceutique Francaise SAS
Original Assignee
Laboratoires Meram Les
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Meram Les filed Critical Laboratoires Meram Les
Application granted granted Critical
Publication of CA1095930A publication Critical patent/CA1095930A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/02—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
    • C07C303/22—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof from sulfonic acids, by reactions not involving the formation of sulfo or halosulfonyl groups; from sulfonic halides by reactions not involving the formation of halosulfonyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
    • C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
    • C07C309/15—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CA299,464A 1977-03-23 1978-03-20 Process for the preparation of new derivatives of taurine having a reinforced neuro-muscular activity Expired CA1095930A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7708692 1977-03-23
FR7708692A FR2384751A1 (fr) 1977-03-23 1977-03-23 Nouveaux derives de la taurine a activite neuro-musculaire renforcee

Publications (1)

Publication Number Publication Date
CA1095930A true CA1095930A (en) 1981-02-17

Family

ID=9188473

Family Applications (1)

Application Number Title Priority Date Filing Date
CA299,464A Expired CA1095930A (en) 1977-03-23 1978-03-20 Process for the preparation of new derivatives of taurine having a reinforced neuro-muscular activity

Country Status (17)

Country Link
US (3) US4199601A (enExample)
JP (1) JPS53149928A (enExample)
AT (1) AT356637B (enExample)
AU (1) AU523705B2 (enExample)
BE (1) BE865163A (enExample)
CA (1) CA1095930A (enExample)
CH (1) CH629479A5 (enExample)
DE (1) DE2810918C2 (enExample)
ES (1) ES468201A1 (enExample)
FR (1) FR2384751A1 (enExample)
GB (1) GB1599962A (enExample)
GR (1) GR62093B (enExample)
IT (1) IT1111455B (enExample)
NL (1) NL7803131A (enExample)
OA (1) OA05914A (enExample)
SE (1) SE443781B (enExample)
ZA (1) ZA781697B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2457281A1 (fr) * 1979-05-23 1980-12-19 Meram Lab Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee
US4915685A (en) * 1986-03-19 1990-04-10 Petelenz Tomasz J Methods and apparatus for iontophoresis application of medicaments at a controlled ph through ion exchange
US5602150A (en) * 1992-10-02 1997-02-11 Research Foundation For Mental Hygiene, Inc. Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia
US6099869A (en) 1995-04-18 2000-08-08 Nutrition 21 Calcium taurate and antihypertensive drug for hypertension
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
ATE251129T1 (de) * 1998-01-27 2003-10-15 Merck Sante Sas Derivatives of aminoalkane sulphonic, phosphonic and phosphinic acids, their preparation and their use as medicaments
CA2369997C (en) * 1999-04-28 2009-11-17 Queen's University At Kingston Compositions and methods for treating amyloidosis
US6562836B1 (en) 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
US6881750B2 (en) * 2003-03-04 2005-04-19 Nutrition Corp. Of America, Ltd. Potassium taurate bicarbonate and ascorbate
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
AU2005310986A1 (en) * 2004-11-12 2006-06-08 Bellus Health (International) Limited Methods and fluorinated compositions for treating amyloid-related diseases
AU2005310979A1 (en) * 2004-11-16 2006-06-08 Bellus Health (International) Limited Compounds for the treatment of CNS and amyloid associated diseases
FR2878160B1 (fr) * 2004-11-19 2008-07-25 Jean Pierre Durlach Utilisation du n-acetyl-taurinate de magnesium pour la preparation de medicaments inhibiteurs de l'hypersensiblite photique
EP1836161B1 (en) * 2004-12-22 2016-07-20 BHI Limited Partnership Methods and compositions for treating amyloid-related diseases
SI2089417T1 (sl) 2006-10-12 2015-04-30 Bhi Limited Partnership Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline
TW200924746A (en) * 2007-09-07 2009-06-16 Xenoport Inc Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2009033079A1 (en) * 2007-09-07 2009-03-12 Xenoport, Inc. Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090099253A1 (en) * 2007-10-15 2009-04-16 Xenoport, Inc. Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use
FR2927809B1 (fr) 2008-02-26 2011-01-14 Tri Inov Nouvelle utilisation de n-acetyl-taurinate de zinc.
RU2453310C1 (ru) * 2010-12-09 2012-06-20 Открытое акционерное общество "Всероссийский научный центр по безопасности биологически активных веществ" (ОАО "ВНЦ БАВ") Средство, обладающее нейропротекторным действием в условиях ишемического поражения мозга и гипоксии, представляющее собой 2-аминоэтансульфонат магния, фармацевтические композиции
FR2973702B1 (fr) 2011-04-08 2013-04-26 Tri Inov N-acetyl-taurinate de zinc pour le traitement du cancer de la prostate
BR112014012918A2 (pt) * 2011-11-29 2017-06-13 Basf Se processo para preparar um sal de ácido, ácido, sal de sódio ácido, e, uso de um ácido
MX365366B (es) 2015-06-17 2019-05-30 Jean Profet Margaret Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
CN112516123B (zh) * 2015-12-25 2022-07-19 北京乳凝创智生物技术研发中心（有限合伙） 一种保健品外用制剂
BE1025644B1 (fr) * 2017-10-13 2019-05-15 Synapharm Industrial Synthesis Compose pour le traitement d'une maladie ou d'un trouble du systeme nerveux central chez un sujet en stimulant et/ou en restaurant la plasticite neuronale
BE1025645B1 (fr) * 2017-10-13 2019-05-15 Synapharm Industrial Synthesis Compose pour le traitement de la neurotoxicite due a l'hyperexcitabilite des recepteurs glutamatergiques ionotropes
EP3738588A1 (en) 2019-05-13 2020-11-18 Margaret Jean Profet Topical and oral formulations comprising taurine and magnesium for use in the treatment of rosacea
WO2020229443A1 (fr) 2019-05-16 2020-11-19 Synapharm Industrial Synthesis Composé et composition pour utilisation dans le traitement du syndrome prémenstruel et/ou du trouble dysphorique prémenstruel
ES2917623T3 (es) 2019-05-16 2022-07-11 Synapharm Ind Synthesis Compuesto y composición para uso en el tratamiento del síndrome premenstrual y/o del trastorno disfórico premenstrual
BE1026955B1 (fr) * 2019-06-11 2020-08-04 Synapharm Ind Synthesis Procédé de fabrication de N-acétyl-taurinate de magnésium
RU2730835C1 (ru) * 2019-10-23 2020-08-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Дикалиевая соль N-(3-гидроксибензоил)таурина, обладающая антиагрегантной и антитромботической активностью в сочетании с церебропротективным действием
RU2731106C1 (ru) * 2019-10-23 2020-08-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ Дикалиевая соль N-(4-гидроксибензоил)таурина, обладающая антиагрегантной и антитромботической активностью
WO2021245697A1 (en) 2020-06-01 2021-12-09 Celagenex Research (India) Pvt. Ltd. Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling
WO2026013679A1 (en) * 2024-07-11 2026-01-15 Celagenex Research (India) Pvt. Ltd. A conjugate compound for regulation of mbp expression and novel in-situ process for preparation thereof.
CN119504517B (zh) * 2025-01-22 2025-04-18 浙江天启生化股份有限公司 一种乙酰牛磺酸镁的制备方法
WO2026162765A1 (en) * 2025-01-31 2026-08-06 Synapharm Industrial Synthesis Compound and compositions for weight management and related conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3232968A (en) * 1959-12-01 1966-02-01 Gen Aniline & Film Corp Process for preparing n-acyl taurates using hypophosphorous acid as catalyst
US3344174A (en) * 1962-08-21 1967-09-26 Monsanto Co Vicinal acylamido sulfonate compounds
DE1256650B (de) * 1965-08-07 1967-12-21 Dr Dieter Arlt Verfahren zur Herstellung von N-acylierten 2-Amino-alkan-sulfonsaeuren-(1) bzw. von 2-Amino-alkan-sulfonsaeuren-(1)
US3544597A (en) * 1969-06-12 1970-12-01 Rohm & Haas Process for manufacturing sulfonated amides
US3960918A (en) * 1973-06-26 1976-06-01 The Lubrizol Corporation Preparation of esters of amidoalkanesulfonic acids

Also Published As

Publication number Publication date
AT356637B (de) 1980-05-12
IT1111455B (it) 1986-01-13
JPS53149928A (en) 1978-12-27
AU523705B2 (en) 1982-08-12
GR62093B (en) 1979-02-22
ZA781697B (en) 1979-03-28
IT7867631A0 (it) 1978-03-22
OA05914A (fr) 1981-06-30
SE443781B (sv) 1986-03-10
FR2384751A1 (fr) 1978-10-20
DE2810918C2 (de) 1985-06-20
NL7803131A (nl) 1978-09-26
GB1599962A (en) 1981-10-07
ES468201A1 (es) 1978-12-01
BE865163A (fr) 1978-09-22
US4271189A (en) 1981-06-02
JPS6256867B2 (enExample) 1987-11-27
SE7803032L (sv) 1978-09-24
ATA202878A (de) 1979-10-15
US4199601A (en) 1980-04-22
FR2384751B1 (enExample) 1979-07-20
DE2810918A1 (de) 1978-09-28
CH629479A5 (fr) 1982-04-30
AU3463478A (en) 1979-10-04
US4267194A (en) 1981-05-12

Similar Documents

Publication Publication Date Title
US4199601A (en) Derivatives of taurine having reinforced neuro-muscular activity
US4355043A (en) Novel derivatives of 3-aminopropanesulfonic acid having a reinforced activity on membrane
US4228099A (en) Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4320146A (en) Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
Meister et al. Diminished phenylketonuria in phenylpyruvic oligophrenia after administration of L-glutamine, L-glutamate or L-asparagine
KEITH et al. The action and excretion of nitrates
EP0186252A2 (en) Use of thiophene compounds for the manufacture of a medicament against tumours
CA1242713A (en) Process for preparation of a new hemin complex compound with medical applications
US4939164A (en) Strontium salt
DE2941288C2 (enExample)
Mehlman et al. Oxidative phosphorylation and respiration by rat liver mitochondria from aspirin-treated rats
SU1227115A3 (ru) Способ получени 17,18-дегидро-аповинкаминол-3',4',5'-триметоксибензоата или его солей
Löffler et al. Influence of dietary purines on pool size, turnover, and excretion of uric acid during balance conditions: Isotope Studies Using15N-Uric Acid
Bajgar Inhibition of acetylcholinesterase in different parts of the rat brain by isopropyl methyl-phosphonofluoridate; in vitro and in vivo experiments
JPH0560447B2 (enExample)
FRIEDMAN Problems of cation-exchange-resin therapy
FI97950B (fi) Menetelmä vitamiinituotteen valmistamiseksi
Snyder et al. A New Synthesis of Homocystine and a Further Improvement in the Synthesis of Methionine
Hanig et al. L-DOPA administration to neonate chicks: effects on behavior and levels of brain biogenic amines
DE2107657C3 (de) Arzneimittel zur Behandlung der durch Eisenmangelerscheinungen und Verfahren zur Herstellung des Natriumsalzes von o-Carboxybenzoylferrocens
Proskouriakoff Some Salts of Levulinic Acid1
Al-Khayat et al. Chelation of ambilhar with calcium and magnesium
Spitzer et al. The effect of colchicine on plasma unesterified fatty acids
VOEGTLIN et al. higher animals (rat) than that exerted on protozoa. Recent observations, however, have shown that it is quite possible to
Zhejiang CLINICAL EVALUATION OF PRAZIQUANTEL IN TREATMENT OF SCHISTOSOMIASIS JAPONICA: A REPORT OF 181 CASES

Legal Events

Date Code Title Description
MKEX Expiry